Naratriptan 1 A Pharma (Naratriptan)

Naratriptan selectively activates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This activation causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade.

The appropriate dose of Naratriptan is determined by a qualified prescriber based on the patient’s clinical condition, medical history, and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for Naratriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the prescribing clinician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Naratriptan is a selective 5‑HT1B/1D agonist, similar to other triptans such as sumatriptan and rizatriptan. Compared with some triptans, it has a longer half‑life and may be preferred for patients who need sustained relief, but individual response and tolerability vary.

Naratriptan tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and keep out of reach of children.

Naratriptan is taken orally as a tablet. The tablet should be swallowed whole with water, preferably as soon as migraine symptoms begin. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include chest pain or tightness, coronary vasospasm, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and rare allergic reactions. Patients experiencing any of these symptoms should seek immediate medical attention.

Naratriptan should be avoided in patients with known coronary artery disease, uncontrolled hypertension, history of stroke or transient ischemic attack, severe hepatic impairment, or those taking contraindicated medications such as ergot alkaloids or MAO inhibitors.